Inhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) Facility

Rhea-AI Summary

Inhibikase Therapeutics (Nasdaq: IKT) sold 25,000,000 shares of common stock to RA Capital Management through its at-the-market (ATM) facility, generating $50 million in gross proceeds. According to the company, the additional capital, together with existing cash, is expected to fund operations through topline data readout in Part B of the global Phase 3 IMPROVE-PAH trial, subject to the full exercise of outstanding Series A and B Warrants.

The shares were issued under an effective shelf registration statement on Form S-3 (File No. 333-288213) and an ATM prospectus supplement filed December 19, 2025. The company emphasized that this announcement is not an offer or solicitation to sell securities in any jurisdiction where such actions would be unlawful.

Positive

• $50 million gross proceeds raised via ATM share sale
• Financing expected to fund operations through Phase 3 IMPROVE-PAH Part B topline, subject to warrant exercise

Negative

• Issuance of 25,000,000 new shares creates equity dilution for existing shareholders
• Runway expectation depends on full exercise of Series A and B Warrants

News Explained

The completed financing supplies cash while expanding the common-share base and reducing existing holders’ percentage ownership.

On July 14, 2026, Inhibikase Therapeutics completed the sale of $50 million of gross proceeds to RA Capital Management by issuing 25 million common shares.

Those additional shares increase the total share count and reduce existing holders’ percentage ownership absent offsetting changes. An ATM facility permits an issuer to sell new shares gradually into the open market at prevailing prices rather than through one single priced deal, and the release identifies this transaction as having occurred through that facility.

The Form S-3 filing authorized capacity for future registered sales but did not itself sell shares, while the 424(b) prospectus supplement states the final terms of a specific takedown. Against first-quarter operating cash use, the offering’s gross proceeds equal 373.1 days, versus 370 days for cash and equivalents at March 31, 2026.

Sources and calculations

• July 14, 2026 Inhibikase Therapeutics ATM sale release (2026-07-14)
• Dilution definition (undated)
• At-the-market program definition (undated)
• Form S-3 purpose (undated)
• Prospectus supplement purpose (undated)
• Inhibikase Therapeutics first-quarter 2026 fundamentals (2026Q1)

• Offering gross vs quarterly operating cash outflow, in days of cash use $50,000,000 / ($12,059,722 / 90) = [object Object]
• Cash and equivalents vs quarterly operating cash outflow, in days of cash use $49,573,510 / ($12,059,722 / 90) = [object Object]

Market reaction after ATM equity offering: IKT +5.10% in the Jul 14 session

+5.10% 3.0x vol

30 alerts

+5.10% Session close to close

+25.3% Peak in 3 hr 44 min

$269.35M Market Cap

3.0x Rel. Volume

In the Jul 14 session, IKT gained 5.10%, reflecting a notable positive market reaction. Argus tracked a peak move of +25.3% during that session. Our momentum scanner triggered 30 alerts that day, indicating elevated trading interest and price volatility. Trading volume was very high at 3.0x the daily average, suggesting strong buying interest.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved +5.1% in the session following this news. If a strong advance followed this ATM equi...

Analysis

The stock moved +5.1% in the session following this news. If a strong advance followed this ATM equity offering, it would contrast with prior modest reactions and could imply investors welcomed the $50 million raised despite dilution. However, elevated short positioning and an effective S-3 shelf leave room for volatility and further capital usage.

Key Figures

Shares sold: 25,000,000 shares Gross proceeds: $50 million

2 metrics

Shares sold 25,000,000 shares Common stock sold to RA Capital Management via ATM facility

Gross proceeds $50 million ATM sale of common stock to RA Capital Management

Historical Context

4 past events · Latest: Jul 02 (Neutral)

Pattern 4 events

Date	Event	Sentiment	24h Move	Catalyst
Jul 02	Equity compensation	Neutral	-0.5%	Inducement grants of stock options to new non-executive employees.
May 12	1Q26 earnings report	Neutral	-1.0%	First quarter 2026 financials and cash position update for IKT-001 program.
Apr 07	Phase 3 trial update	Positive	-1.7%	First patient enrollment in global Phase 3 IMPROVE-PAH study of IKT-001.
Mar 26	FY25 earnings report	Positive	+3.1%	Full-year 2025 results and capital raise supporting Phase 3 IMPROVE-PAH program.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent Inhibikase headlines, including clinical, financing, and governance updates, have typically produced modest single-digit percentage reactions in either direction.

Key Terms

at-the-market, atm facility, shelf registration statement, form s-3, +1 more

5 terms

at-the-market financial

"through its at-the-market (“ATM”) facility for gross proceeds"

"At-the-market" is a method for companies to sell new shares of stock directly into the open market over time, rather than all at once. It allows companies to raise money gradually, similar to selling slices of a pie instead of the entire pie at once, which can help manage the sale's impact on the stock price. This approach gives investors a steady supply of shares while providing companies with flexible funding options.

atm facility financial

"through its at-the-market (“ATM”) facility for gross proceeds"

An ATM facility (short for “at‑the‑market” facility) is a way for a company to raise money by selling newly issued shares directly into the open market at prevailing prices through an intermediary. Think of it like selling slices of a pie one at a time at whatever buyers are willing to pay; it gives the company flexible, on‑demand access to cash but can increase the number of shares outstanding and put downward pressure on the stock price, which matters to investors' ownership and per‑share value.

shelf registration statement regulatory

"pursuant to a shelf registration statement on Form S-3"

A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.

form s-3 regulatory

"a shelf registration statement on Form S-3 (File No. 333-288213)"

Form S-3 is a legal document companies use to register their stock sales with the government, making it easier and faster for them to raise money by selling shares to investors. It’s like having a pre-approved shopping list that lets a company quickly sell new shares when they need funds, without going through a lengthy approval process each time.

rule 424(b) regulatory

"prospectus supplement relating to the ATM offering filed with the SEC pursuant to Rule 424(b)"

Rule 424(b) is a U.S. Securities and Exchange Commission requirement that companies file the exact prospectus or prospectus supplement they use to sell securities after a registration statement becomes effective. Think of it as the official posting of the final sales brochure so investors can see the precise terms, risks and use of proceeds; it matters because it ensures transparency, helps investors compare offerings and confirms the issuer complied with disclosure rules.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WILMINGTON, Del., July 14, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary Arterial Hypertension (“PAH”), today announced that it has sold 25,000,000 shares of the Company’s common stock to RA Capital Management through its at-the-market (“ATM”) facility for gross proceeds of $50 million.

The Company expects that the additional capital raised through this financing, together with existing cash reserves, will support operations through topline data readout in Part B of the Company’s ongoing global Phase 3 IMPROVE-PAH clinical study, subject to the full exercise of the outstanding Series A and B Warrants.

The shares of common stock described above were sold by the Company pursuant to a shelf registration statement on Form S-3 (File No. 333-288213), which was declared effective by the SEC on June 27, 2025, and a prospectus supplement relating to the ATM offering filed with the SEC pursuant to Rule 424(b) under the Securities Act of 1933, as amended, on December 19, 2025 (the “ATM prospectus supplement”). Electronic copies of the ATM prospectus supplement and the accompanying prospectus are available on the SEC's website at http://www.sec.gov.

This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in the offering, nor shall there be any sale of these securities in any jurisdiction in which an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

About Inhibikase 
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) is a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (“PAH”), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as “c-Kit,” has been implicated. Our lead product candidate is IKT-001, a prodrug of imatinib mesylate (“imatinib”), for PAH which is an orphan indication. Imatinib was first approved in the United States in 2001 for various cancers and blood disorders and, following more than 20 years of clinical use, has a well-characterized safety profile with the first reported use of imatinib in PAH occurring in 2005. PAH is a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance that affects approximately 50,000 Americans. Our single pivotal Phase 3 clinical study in PAH in approximately 180 sites around the world, named IMPROVE-PAH (IKT-001 for Measuring Pulmonary Vascular Resistance and Outcome Variables in a Phase 3 Evaluation of PAH), is actively enrolling patients.

Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking terminology such as “believes,” “expects,” “may,” “will,” “should,” “anticipates,” “plans,” or similar expressions or the negative of these terms and similar expressions are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements that express the Company’s intentions, beliefs, expectations, strategies, predictions or any other statements related to the Company’s expected cash runway. These forward-looking statements are based on Inhibikase’s current expectations and assumptions. Such statements are subject to certain risks and uncertainties, which could cause Inhibikase’s actual results to differ materially from those anticipated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include our ability to execute a Phase 3 study to evaluate IKT-001 as a treatment for PAH, as well as such other factors that are included in our periodic reports on Form 10-K and Form 10-Q that we file with the U.S. Securities and Exchange Commission. Any forward-looking statement in this release speaks only as of the date of this release. Inhibikase undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.

Contacts:
Investor Relations:
Michael Moyer
LifeSci Advisors
mmoyer@lifesciadvisors.com

FAQ

What did Inhibikase Therapeutics (NASDAQ: IKT) announce on July 14, 2026?

Inhibikase Therapeutics announced it sold 25,000,000 common shares to RA Capital Management for $50 million in gross proceeds. According to the company, the sale was executed through its at-the-market facility under an effective Form S-3 shelf registration and ATM prospectus supplement.

How much capital did Inhibikase Therapeutics (IKT) raise in its 2026 ATM offering?

Inhibikase Therapeutics raised $50 million in gross proceeds by selling 25,000,000 common shares through its ATM facility. According to the company, these funds, combined with existing cash, are expected to support operations through Phase 3 IMPROVE-PAH Part B topline, subject to warrant exercise.

How will the $50 million ATM financing impact Inhibikase Therapeutics’ Phase 3 IMPROVE-PAH trial?

The company expects the $50 million, together with existing cash, to fund operations through topline data for Part B of the global Phase 3 IMPROVE-PAH study. According to Inhibikase, this projection is subject to full exercise of outstanding Series A and B Warrants.

Who bought the new Inhibikase Therapeutics (IKT) shares in the July 2026 ATM transaction?

RA Capital Management purchased 25,000,000 shares of Inhibikase Therapeutics common stock in the July 2026 ATM transaction. According to the company, these shares were issued under its Form S-3 shelf registration and a December 19, 2025 ATM prospectus supplement filed with the SEC.

Under what SEC registration did Inhibikase Therapeutics (IKT) sell the 25 million ATM shares?

The 25 million shares were sold under a shelf registration statement on Form S-3 (File No. 333-288213). According to Inhibikase, the SEC declared this registration effective June 27, 2025, and an ATM prospectus supplement was filed on December 19, 2025 under Rule 424(b).

Does the July 2026 Inhibikase Therapeutics ATM share sale constitute an offer to sell securities broadly?

No, the company stated the press release does not constitute an offer to sell or solicit offers to buy securities. According to Inhibikase, no sale will occur in any jurisdiction where such activity would be unlawful without proper registration or qualification.